Navigation Links
Versatility of 454 Sequencing(TM) Demonstrated in Three Publications in Science Last Week
Date:10/2/2007

Variety of new applications spans paleogenomics, paired-end mapping, and

gene expression analysis

BRANFORD, Conn., Oct. 2 /PRNewswire/ -- 454 Life Sciences, a Roche company, is the subject of three ground-breaking studies published last week in Science, all of which employed the company's Genome Sequencer(TM) system. The studies, entitled "Paired-End Mapping Reveals Extensive Genomic Structural Variation in Humans", "Wasp Brain Gene Expression Supports an Evolutionary Link between Maternal Behavior and Eusociality", and "Whole-Genome Shotgun Sequencing of Mitochondria from Ancient Hair Shafts" appear online (ahead of print) in Science Express.

The three publications span a number of research fields and sequencing applications. The diversity of the publications illustrate the flexibility of 454 Sequencing and its ability to deliver scientifically relevant results in any research field employing DNA sequencing. The studies relied on long, highly accurate reads, including paired reads, characteristic of 454 Sequencing.

Previous studies of human genomic variation tended to look at changes called single nucleotide polymorphism (SNP), variations that involve just one nucleotide. However, the study, "Paired-End Mapping Reveals Extensive Genomic Structural Variation in Humans," published today suggests that structural variation is responsible for a larger number of differences between the genomes of two individuals than SNPs. Furthermore, structural variation may have notable physical effects on an individual. The role that SV plays in human variability has not been well understood because of imprecise technology used in previous research. The novel approach described today in Science, called Paired End Mapping (PEM), used 454 Sequencing to comprehensively study SV at an unmatched level of resolution, detecting most of the structural variation in the human genome.

The presence of worker wasps that forgo reproduction
'/>"/>

SOURCE 454 Life Sciences
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Study Shows Ixabepilone Demonstrated Clear Activity in Patients with Metastatic Breast Cancer Resistant to Anthracycline, Taxane, and Capecitabine
2. Data Demonstrated Saxagliptin Added to Metformin Improved Glycemic Control in Subjects with Type 2 Diabetes Compared to Metformin Alone
3. Data Demonstrated Saxagliptin Added to Metformin Improved Glycemic Control in Subjects with Type 2 Diabetes Compared to Metformin Alone
4. Investigational Study Demonstrated a Re-Establishment of Clinical Improvement with Orencia (Abatacept) in Children with Juvenile Idiopathic Arthritis upon Re-Introduction of Therapy
5. Study Demonstrated Rozerem (ramelteon) Does Not Affect Middle-of-the-Night Balance in Older Adults with Insomnia
6. Repros Reports That Proellex Has Demonstrated Superior Efficacy and Safety in Endometriosis When Compared to Standard of Drug Care
7. Organons Sugammadex Demonstrated a 9-12 Times Faster Recovery in Phase III Pivotal Trial as Compared to Neostigmine
8. Organons Sugammadex Demonstrated a 9-12 Times Faster Recovery in Phase III Pivotal Trial Compared to Neostigmine
9. Trexima (Sumatriptan/Naproxen Sodium) Demonstrated Migraine-Free Response Across Multiple Attacks
10. Data Demonstrated Metastatic Melanoma Response to Investigational Immunotherapy Ipilimumab
11. Long-Term Pegylated Interferon Alfa-2b Therapy in Stage III Melanoma Demonstrated Significant and Sustained Impact on Relapse-Free Survival
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2008)...irstCall/ -- Leaders of Schering-Plough Corporatio...stors on the company,s research pipeline, highligh... 46 new entities in clinical trials or under regul..., "Research and development is adding strength ...transformation," said Fred Hassan, chairman and CE...
(Date:11/24/2008)...ship and long-term commitment to hepatitis researc...-FirstCall/ -- Schering-Plough Corporation (NYSE: ...evir, its lead investigational oral hepatitis C pr...t. The company believes boceprevir has the potent...ase inhibitor for treating chronic hepatitis C. T...
(Date:11/24/2008)...irstCall/ -- Schering-Plough Corporation (NYSE: ...nd selective adenosine2a receptor antagonist, met ...ial in patients suffering from moderate to severe ...s and abnormal involuntary movements (dyskinesias)...ompany,s 2008 R&D Update meeting being hosted ...
(Date:11/24/2008)...-FirstCall/ -- GeneThera, Inc.,(Pink Sheets: GTHR...al Time,PCR test for Johne,s disease through its ...is set to begin offering its Johne,s disease testi... to GeneThera Chairman, Dr. Tony Milici MD,Ph.D.... for Johne,s disease,called HerdGuard(TM) by the...
Breaking Medicine Technology:Schering-Plough Highlights R&D Pipeline Progress, Innovation and Breadth of Research Projects 2Schering-Plough Highlights R&D Pipeline Progress, Innovation and Breadth of Research Projects 3Schering-Plough Highlights R&D Pipeline Progress, Innovation and Breadth of Research Projects 4Schering-Plough Highlights R&D Pipeline Progress, Innovation and Breadth of Research Projects 5Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 2Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 3Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 4Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 5Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 6Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 7Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 8Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 9Schering-Plough Reports Preladenant Meets Primary Endpoint in Phase II Dose-Finding Trial for Parkinson's Disease 2Schering-Plough Reports Preladenant Meets Primary Endpoint in Phase II Dose-Finding Trial for Parkinson's Disease 3Schering-Plough Reports Preladenant Meets Primary Endpoint in Phase II Dose-Finding Trial for Parkinson's Disease 4GeneThera Announces it is Set to Begin Commercial Testing for Johne's Disease as Soon as January, 2009. 2GeneThera Announces it is Set to Begin Commercial Testing for Johne's Disease as Soon as January, 2009. 3GeneThera Announces it is Set to Begin Commercial Testing for Johne's Disease as Soon as January, 2009. 4Mood Disorders Put Breast Cancer Patients at Risk for PTSD 18921 1Mood Disorders Put Breast Cancer Patients at Risk for PTSD 18921 2U S Air Force Pays Record Amount for Baby Injured in Government Hospital 18918 1U S Air Force Pays Record Amount for Baby Injured in Government Hospital 18918 2Can Wireless Technologies Rescue U S Hospitals 3F 18914 1Can Wireless Technologies Rescue U S Hospitals 3F 18914 2Roches Vidal Honored as 2008 HBA Rising Star 18911 1Roches Vidal Honored as 2008 HBA Rising Star 18911 2
... from ongoing phase I/II trial,of oncolytic HSV * ...conference , MARTINSRIED, Germany, June 29, 2007.-... Standard: MDG) announces that a case,report from ...lling,virus will be presented in a press conferenc...y. Out of more than 300 posters accepted,for the c...
...er vaccine has shown 90%,efficacy for prevention o...ted with the human papillomavirus (HPV) types targ...e published early Online,and in the upcoming issue...0% or more,cases of cervical cancer worldwide, but...contribute to cervical cancer. , Professor Jorma P...
Other Medicine Technology:European Society for Medical Oncology (ESMO) Presents Data from the,Clinical Trial of MediGene's Cancer-Killing Virus in Press,Conference 2Vaccine Can Prevent Cervical Cancer and Precancerous Lesions 2
(Date:12/1/2008)...sta is pleased to announce it,has reached an agre... leading,pharmaceutical companies, to dispense th...Welvista,s no-cost prescription medication program...rom the company,s Patient Assistance,Programs (PA...or the,uninsured. Including sanofi-aventis, Welvi...
(Date:12/1/2008)...tCall/ -- Pressure BioSciences, Inc. (Nasdaq: PB...mprehensive restructuring program designed to sign..., and refocus the Company,s business strategy in s...und significant market acceptance. The restructur... personnel of eight full-time employees (40% of th...
(Date:12/1/2008)...her special needs, report shows , , MOND...c children are more likely to see their sons or da...rnment report shows. , Data from the National ... also indicated that when compared with families t...ical needs, parents caring for autistic children f...
(Date:12/1/2008)...ncerned that the global financial crisis will lead...ntries, leaders of the world,s largest agricultura...tively modest, well-targeted investments could gre... of people living on less than $1 a day. , Speak...p on International Agricultural Research (CGIAR) i...
Breaking Medicine News(10 mins):Health News:Welvista Announces Partnering with sanofi-aventis U.S. to Provide Medication at No Cost to the Uninsured 2Health News:Pressure BioSciences, Inc. Announces Restructuring, Significant Cost Reduction Initiatives, and Sharpened Focus 2Health News:Pressure BioSciences, Inc. Announces Restructuring, Significant Cost Reduction Initiatives, and Sharpened Focus 3Health News:Pressure BioSciences, Inc. Announces Restructuring, Significant Cost Reduction Initiatives, and Sharpened Focus 4Health News:Pressure BioSciences, Inc. Announces Restructuring, Significant Cost Reduction Initiatives, and Sharpened Focus 5Health News:Pressure BioSciences, Inc. Announces Restructuring, Significant Cost Reduction Initiatives, and Sharpened Focus 6Health News:Pressure BioSciences, Inc. Announces Restructuring, Significant Cost Reduction Initiatives, and Sharpened Focus 7Health News:Health Needs of Autistic Children Often Unmet 2Health News:Health Needs of Autistic Children Often Unmet 3Health News:Experts: Targeted agricultural investments will yield high results, slash poverty in Africa 2Health News:Experts: Targeted agricultural investments will yield high results, slash poverty in Africa 3Health News:Experts: Targeted agricultural investments will yield high results, slash poverty in Africa 4
...ublished in the Lancet, researchers had suggested ...ough high risk HPV virus might vary from country t...ly being developed against two types of virus that...8—may prevent a larger proportion of high-risk HPV...
...therapy with the new biologic drug adalimumab and ... more effective for people with long-standing rheu...ment // with methotrexate alone. It has been found...ts who fail to respond to standard treatment. At ...
... recent study states that rich people could be hap...rs like physical health, income, education and mar...p of people ranging in age from 20 to 64 years. Th...ir age, total family income and general happiness....
...15.The health authorities and the state administra...icism for their inadequate handling of the Mumbai ... the damage already done to their image//. The he...missions of new patients Monday as the outbreak of...
Other Medicine News:
For treatment of carpal tunnel syndrome, mild to moderate wrist sprain, arthritic pain, or following cast removal. The perforated suede finish glove provides support and compression to the wrist, wi
Premium Tennis Elbow Support is 2" wide with loop-lock contact closure and is foam-lined for comfort.
The IROM Elbow is ideal for fixed or controlled ROM in the treatment of stable supracondylar fractures, stable radial fractures, and lateral/medial epicondylitis.
Designed to provide comfortable immobilization of the elbow
Medicine Products: